Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $60.4 million.

  • Spyre Therapeutics' Shares Outstanding (Weighted Average) rose 1871.66% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 1871.66%. This contributed to the annual value of $47.0 million for FY2024, which is 58185.0% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Shares Outstanding (Weighted Average) is $60.4 million, which was up 1871.66% from $60.3 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $82.2 million for Q2 2022, and its period low was $2.6 million during Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $47.0 million (2024), whereas its average is $38.7 million.
  • Per our database at Business Quant, Spyre Therapeutics' Shares Outstanding (Weighted Average) tumbled by 9535.01% in 2023 and then skyrocketed by 108548.12% in 2024.
  • Spyre Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $2.6 million in 2021, then increased by 28.19% to $3.4 million in 2022, then soared by 104.59% to $6.9 million in 2023, then surged by 581.85% to $47.0 million in 2024, then increased by 28.47% to $60.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $60.4 million in Q3 2025, compared to $60.3 million in Q2 2025 and $60.3 million in Q1 2025.